The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line

Research output: Contribution to journalJournal articleResearchpeer-review

  • Cecilie Hurup Hansen
  • Lizette Weber Larsen
  • Amalie Møller Sørensen
  • Bent Halling-Sørensen
  • Styrishave, Bjarne

Selective serotonin reuptake inhibitors (SSRIs) used as first line of treatment in major depressive disorder (MDD) are known to exert negative effects on the endocrine system and fertility. The aim of the present study was to investigate the possible endocrine disrupting effect of six SSRIs, fluoxetine, paroxetine, citalopram and its active enantiomer escitalopram, sertraline and fluvoxamine using the OECD standardized and validated human in vitro adrenocortical H295R cell assay. All the major steroids, including progestagens, corticosteroids, androgens and estrogens were analysed using a fully validated LC-MS/MS method. All 6 SSRIs were found to exert endocrine disrupting effects on steroid hormone synthesis at concentrations just around Cmax. Although the mechanisms of disruption were all different, they all resulted in decreased testosterone levels, some due to effects on CYP17, some earlier in the pathway. Furthermore, all SSRIs relatively increased the estrogen/androgen ratio, indicating stimulating effects on the aromatase. Our study demonstrates the potential of SSRIs to interfere with steroid production in the H295R cells around Cmax levels and indicates that these drugs should be investigated further to determine any hazards for the users.

Original languageEnglish
JournalToxicology in Vitro
Pages (from-to)1-11
Number of pages11
Publication statusPublished - Jun 2017

    Research areas

  • Journal Article

ID: 185721031